Demonstrates that a novel amphiphilic conjugate alleviates epilepsy through ferroptosis suppression in neural cells, indicating a potential therapeutic strategy.
There has been a lack of effective and safe therapies for temporal lobe epilepsy (TLE), a typical refractory epilepsy. Lipid peroxidation, a critical ferroptotic event, is key for TLE, and targeting this ferroptotic process represents a promising therapeutic approach. However, selective suppression of ferroptosis in neural cells is challenging because of the plasma instability of canonical ferroptosis inhibitors and the presence of the blood-brain barrier (BBB). Here, we report an amphiphilic glycerylphosphoryl choline-ebselen conjugate (GPC-EBS), a biomimic of glutathione peroxidase 4 (GPX4), for effective suppression of ferroptosis and alleviation of TLE. The conjugate addressed the poor water solubility of EBS well and self-assembled with a helper lipid (DSPE-PEG 2000), forming a nanoscale micelle (mGPC-EBS). mGPC-EBS could efficiently suppress lipid peroxidation in neural cell lines. Following nasal delivery that bypasses the blood-brain barrier, mGPC-EBS micelles showed potent antiseizure and neuroprotective effects in an acute epilepsy mouse model. Meanwhile, mGPC-EBS suppressed spontaneous recurrent seizures and ameliorated cognitive deficits in a chronic epilepsy mouse model. Mechanistic investigation revealed that mGPC-EBS, apart from its GPX4-mimic role, downregulated tripartite motif-containing 21 (TRIM21) and led to an increase in GPX4 as TRIM21 can ubiquitylate and degrade GPX4. The current work provides a strategy to manipulate GPX4 activity using tailored organoselenium conjugates for the effective management of refractory TLE.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: